Choose your preferred way to stay informed of new case launches and settlement deadlines
The U.S. Food and Drug Administration (“FDA”) posted briefing documents in advance of meeting of the Oncologic Drugs Advisory Committee, scheduled for March 15, 2024, regarding Bristol Myers’s CAR-T cell therapy Abecma. The briefing documents noted that Abecma was linked to earlier deaths, citing late-stage clinical trial data submitted by Bristol Myers. Following this news, on March 13, 2024, Bristol Myers’s stock price fell over 3%.
In order to be eligible to join the BMY class action lawsuit, you must have incurred a loss on shares of Bristol-Myers Squibb Company purchased during the class period listed above.
TOP
